CemiplimAb Survivorship Epidemiology (CASE)

General Information Age Group Adults Status Recruiting Protocol Number NCT03836105 Background Information This is a prospective survivorship study of adult patients with Cutaneous Squamous cell Carcinoma (CSCC) who receive treatment with commercially available cemiplimab. The objectives of the study are to identify potential determinants of disease progression, Quality of Life (QOL), and other health-related outcomes. The study also looks to assess patient experience, QOL and functional status, in a real-world setting for patients with CSCC. The information collected from the study will be used to better understand the long-term effectiveness and safety of cemiplimab-rwlc in patients. Cemiplimab-rwlc has been approved by the U.S. FDA for treatment of advanced cutaneous squamous cell carcinoma. Offered At Inova Schar Cancer Institute 8081 Innovation Park Drive Fairfax, VA 22031A department of Inova Fairfax Hospital Eligibility Information Adult male and/or female subjects between the ages of 18 and 70 years receiving treatment with cemiplimab for CSCC, or initiating treatment with cemiplimab for CSCC Additional eligibility in protocol Ineligibility Information Patients receiving cemiplimab for an indication other than CSCC Additional ineligibility in protocol For more information go to: https://clinicaltrials.gov/ct2/show/NCT03836105 Contact Information Contact Name Hunfa Asghar Contact Phone 571-472-0626 Contact Email Send Email